Liquid biomarkers in melanoma: detection and discovery
Open Access
- 17 January 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 17 (1), 1-14
- https://doi.org/10.1186/s12943-018-0757-5
Abstract
A vast array of tumor-derived genetic, proteomic and cellular components are constantly released into the circulation of cancer patients. These molecules including circulating tumor DNA and RNA, proteins, tumor and immune cells are emerging as convenient and accurate liquid biomarkers of cancer. Circulating cancer biomarkers provide invaluable information on cancer detection and diagnosis, prognosticate patient outcomes, and predict treatment response. In this era of effective molecular targeted treatments and immunotherapies, there is now an urgent need to implement use of these circulating biomarkers in the clinic to facilitate personalized therapy. In this review, we present recent findings in circulating melanoma biomarkers, examine the challenges and promise of evolving technologies used for liquid biomarker discovery, and discuss future directions and perspectives in melanoma biomarker research.Keywords
Funding Information
- National Health and Medical Research Council (1130423)
- National Health and Medical Research Council (1093017)
- Cure Cancer Australia Foundation (1123911)
- National Health and Medical Research Council (1104503)
This publication has 154 references indexed in Scilit:
- EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesLeukemia, 2012
- Secreted microRNAs: a new form of intercellular communicationTrends in Cell Biology, 2012
- Standardizing immunophenotyping for the Human Immunology ProjectNature Reviews Immunology, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- MicroRNAs in body fluids—the mix of hormones and biomarkersNature Reviews Clinical Oncology, 2011
- MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteinsNature, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Isolation of rare circulating tumour cells in cancer patients by microchip technologyNature, 2007
- Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patientsInternational Journal of Cancer, 2007